VC Editor- Boston Business Journal
The Kraft Group, owner of the New England Patriots and numerous other businesses, has made a "significant investment" into Southborough-based SynapDx, which is developing an early detection blood-based test for autism spectrum disorder.
The size of the investment wasn't disclosed. The funding follows $6 million in funding in December from North Bridge Venture Partners and General Catalyst Partners and $2 million in February from Laboratory Corporation of America Holdings (NYSE: LH).
The funding from Foxborough-based Kraft Group will support further studies of the autism diagnostic test, which aims to help identify children with autism at an earlier age.
Collaborators of SynapDx include Boston Children’s Hospital and sequencing technology firm Illumina.Back to all News